Tiger X Medical (CDOM), BioCardia Enter Merger Agreement (OPK)
- Wall Street dips as telecoms slump; AmEx surges
- Microsoft (MSFT) Tops Q1 EPS by 8c
- AMD (AMD) Posts Q3 Operating EPS of 3c; Sees Q4 Revenue Down Sequentially
- AT&T (T) Said to Discuss Idea of Takeover in Time Warner (TWX) Meetings
- After-Hours Stock Movers 10/20: (CERC) (ALKS) (PFPT) (MSFT) Higher; (SKX) (RRGB) (AMD) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, announced today that it has entered into a definitive agreement to merge with Tiger X Medical, Inc. (OTC: CDOM). The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia.
The combined entity is expected to have $23 million in cash at closing, which will be used to support the ongoing Phase III Heart Failure Trial, for the commercialization and development of other product candidates, and for general corporate purposes. OPKO Health Inc. (Nasdaq: OPK) will become a significant stockholder in Tiger X Medical and will also serve as an advisor to the business.
“Our CardiAMP cell therapy is seeking to address an enormous unmet need – a treatment for heart failure that develops after a patient has had a heart attack. The merger will provide resources necessary to continue our Phase III development of CardiAMP,” said Dr. Peter Altman, BioCardia’s CEO.
BioCardia is commencing a Phase III study of its CardiAMP cell therapy system for the treatment of heart failure. The Food and Drug Administration (FDA) has approved the study under an Investigational Device Exemption (IDE). The Centers for Medicaid and Medicare Services (CMS) have approved this IDE Nationally as qualified for CMS reimbursement.
The CardiAMP cell therapy for heart failure integrates a proprietary biomarker panel to identify candidates likely to respond to therapy, a cell processing system which prepares a proprietary, high-dosage formulation of autologous bone marrow-derived cells and a unique transendocardial delivery system that ensures efficient and consistent targeted delivery.
The CardiAMP clinical trial is a randomized, controlled, multi-center study of 250 patients evaluating CardiAMP Therapy at up to 40 clinical sites in the United States. It follows two previous clinical studies sponsored by BioCardia supporting the CardiAMP Therapy. Additional details are available via ClinicalTrials.gov, using identifier: NCT02438306.
Results from the trial will be reviewed under the PMA regulations by the FDA’s Center for Biologics Evaluation and Research (CBER) division.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crown Castle (CCI) Misses Q3 AFFO by 2c, Revenues Beats
- salesforce.com (CRM) Takeover Target Wish List Exposed in Colin Powell E-Mail Hack
- Williams Partners (WPZ), Crestwood EP (CEQP), Chesapeake (CHK) Enter Restructuring Agreement for Powder River Basin Services
Create E-mail Alert Related CategoriesCorporate News, Mergers and Acquisitions
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!